UDP glukuronoziltransferaza 1 familija, polipeptid A1
(преусмерено са UDP glucuronosyltransferase 1 family, polypeptide A1)
UDP-glukuronoziltransferaza 1-1 takođe poznata kao UGT-1A je enzim koji je kod ljudi kodiran UGT1A1 genom.[1][2]
UGT-1A je uridin difosfat glukuronoziltransferaza (UDP-glukuronoziltransferaza, UDPGT), enzim glukuronidacionog pata koji transformiše male lipofilne (u masti rastvorlkive) molekule kao što su steroidi, bilirubin, hormoni, i lekovi, u vodi rastvorne, izlučive metabolite.[3]
Reference[уреди | уреди извор]
- ^ Mackenzie PI, Owens IS, Burchell B, Bock KW, Bairoch A, Bélanger A, Fournel-Gigleux S, Green M, Hum DW, Iyanagi T, Lancet D, Louisot P, Magdalou J, Chowdhury JR, Ritter JK, Schachter H, Tephly TR, Tipton KF, Nebert DW (август 1997). „The UDP glycosyltransferase gene superfamily: recommended nomenclature update based on evolutionary divergence”. Pharmacogenetics. 7 (4): 255—69. PMID 9295054. doi:10.1097/00008571-199708000-00001.
- ^ Strassburg CP, Manns MP, Tukey RH (април 1998). „Expression of the UDP-glucuronosyltransferase 1A locus in human colon. Identification and characterization of the novel extrahepatic UGT1A8”. J. Biol. Chem. 273 (15): 8719—26. PMID 9535849. doi:10.1074/jbc.273.15.8719
.
- ^ „Entrez Gene: UGT1A1 UDP glucuronosyltransferase 1 family, polypeptide A1”.
Literatura[уреди | уреди извор]
- Tukey RH, Strassburg CP (2000). „Human UDP-glucuronosyltransferases: metabolism, expression, and disease.”. Annu. Rev. Pharmacol. Toxicol. 40: 581—616. PMID 10836148. doi:10.1146/annurev.pharmtox.40.1.581.
- Kadakol A, Ghosh SS, Sappal BS, Sharma G, Chowdhury JR, Chowdhury NR (2000). „Genetic lesions of bilirubin uridine-diphosphoglucuronate glucuronosyltransferase (UGT1A1) causing Crigler-Najjar and Gilbert syndromes: correlation of genotype to phenotype.”. Hum. Mutat. 16 (4): 297—306. PMID 11013440. S2CID 24275067. doi:10.1002/1098-1004(200010)16:4<297::AID-HUMU2>3.0.CO;2-Z.
- King CD, Rios GR, Green MD, Tephly TR (2001). „UDP-glucuronosyltransferases.”. Curr. Drug Metab. 1 (2): 143—61. PMID 11465080. doi:10.2174/1389200003339171.
- Bosma PJ (2003). „Inherited disorders of bilirubin metabolism.”. J. Hepatol. 38 (1): 107—17. PMID 12480568. doi:10.1016/S0168-8278(02)00359-8.
- Innocenti F, Ratain MJ (2003). „Irinotecan treatment in cancer patients with UGT1A1 polymorphisms.”. Oncology (Williston Park, N.Y.). 17 (5 Suppl 5): 52—5. PMID 12800608.
- Lee W, Lockhart AC, Kim RB, Rothenberg ML (2005). „Cancer pharmacogenomics: powerful tools in cancer chemotherapy and drug development.”. Oncologist. 10 (2): 104—11. PMID 15709212. doi:10.1634/theoncologist.10-2-104.
- Navarro SL, Peterson S, Chen C, Makar KW, Schwarz Y, King IB, Li SS, Li L, Kestin M, Lampe JW (2009). „Cruciferous vegetable feeding alters UGT1A1 activity: diet and genotype-dependent changes in serum bilirubin in a controlled trial.”. Cancer Prev. Res. 2 (4): 345—52. PMC 2666928 . PMID 19336732. doi:10.1158/1940-6207.CAPR-08-0178.
- Barbarino JM, Haidar CE, Klein TE, Altman RB (март 2014). „PharmGKB summary: very important pharmacogene information for UGT1A1”. Pharmacogenet Genomics. 24 (3): 177—83. PMC 4091838 . PMID 24492252. doi:10.1097/FPC.0000000000000024.
